Adjuvant! Online does not significantly influence adjuvant chemotherapy decisions of a breast cancer multidisciplinary team (MDT): a prospective study
recurrent disease were excluded. Once MDT adjuvant therapy decisions were made, the 10-year risk of breast cancer-related death and survival benefit of adjuvant CT were calculated using Adjuvant! Online. Any change to the original MDT recommendations as a result of this information was recorded.
MDT adjuvant therapy decisions included CT (n = 56), radiotherapy (n = 96) and endocrine therapy (n = 89). The numerical estimates from Adjuvant! Online only changed the management of one patient by showing a marginal (3.8%) survival benefit with CT, prompting the MDT to reverse its original decision of not to offer CT to this patient.
Despite the NICE recommendations, these results confirm our previous findings [3] and that of others [4] that routine use of Adjuvant! Online or similar aids does not significantly contribute to MDT decision making by a group of experienced breast cancer clinicians. In fact, Lende et al. [4] recently demonstrated that mitotic activity index was a superior prognostic tool to Adjuvant! Online in lymph node-negative patients <55 years of age. Together these findings suggest that Adjuvant! Online, while not routinely beneficial, may however be useful on a selective basis in a small number of cases where there is difficulty reaching a consensus. 
